Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 68

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Wang, Chuqi, Tan, Jordan Yong Ming, Chitkara, Nishtha, Bhatt, Shruti · 2024 · Cancers

Abstract

Mutation in p53 is the most frequent event in cancer development and a leading cause of cancer therapy resistance due to evasion of the apoptosis cascade. Beyond chemotherapies and radiation therapies, growing evidence indicates that p53-mutant tumors are resistant to a broad range of immune-based therapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T, and hematopoietic stem cell transplantation (HSCT). This highlights the role of p53 mutations in driving immune evasion of tumor cells. In this review, we first summarize recent studies revealing mechanisms by which p53-mutant tumors evade immune surveillance from T cells, natural killer (NK) cells, and macrophages. We then review how these mutant tumor cells reshape the tumor microenvironment (TME), modulating bystander cells such as macrophages, neutrophils, and regulatory T (Treg) cells to foster immunosuppression. Additionally, we review clinical observations indicative of immune evasion associated with p53 loss or mutations. Finally, we discuss therapeutic strategies to enhance immune response in p53 wild-type (WT) or mutant tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16173069

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 82

  1. Ge, 2022, Crosstalk between metabolic reprogramming and epigenetics in cancer: Updates on mechanisms and therapeutic opportunities, Cancer Commun., 42, 1049, 10.1002/cac2.12374 · DOI · Paper page
  2. Zhang, 2018, Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases, Nat. Commun., 9, 3953, 10.1038/s41467-018-06146-9 · DOI
  3. Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin. Cancer Res., 12, 1157, 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
  4. Lane, 1992, p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  5. Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  6. Brady, 2011, Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression, Cell, 145, 571, 10.1016/j.cell.2011.03.035 · DOI · Paper page
  7. Rivlin, 2011, Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889 · DOI · Paper page
  8. Roszkowska, K.A., Piecuch, A., Sady, M., Gajewski, Z., and Flis, S. (2022). Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches. Int. J. Mol. Sci., 23. · DOI
  9. Alvarado-Ortiz, E., de la Cruz-López, K.G., Becerril-Rico, J., Sarabia-Sánchez, M.A., Ortiz-Sánchez, E., and García-Carrancá, A. (2021). Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front. Cell Dev. Biol., 8. · DOI · Paper page
  10. Geske, 2000, DNA repair is activated in early stages of p53-induced apoptosis, Cell Death Differ., 7, 393, 10.1038/sj.cdd.4400663 · DOI
  11. Zhu, K.-L., Su, F., Yang, J.-R., Xiao, R.-W., Wu, R.-Y., Cao, M.-Y., Ling, X.-L., and Zhang, T. (2024). TP53 to mediate immune escape in tumor microenvironment: An overview of the research progress. Mol. Biol. Rep., 51. · DOI
  12. Zhou, 2022, Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246, Br. J. Cancer, 127, 2060, 10.1038/s41416-022-01971-8 · DOI
  13. Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  14. Saha, 2013, Targeting p53 by small molecules in hematological malignancies, J. Hematol. Oncol., 6, 23, 10.1186/1756-8722-6-23 · DOI
  15. Malekzadeh, 2019, Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers, J. Clin. Investig., 129, 1109, 10.1172/JCI123791 · DOI · Paper page
  16. Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
  17. Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
  18. Lepre, M.G., Omar, S.I., Grasso, G., Morbiducci, U., Deriu, M.A., and Tuszynski, J.A. (2017). Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA. Molecules, 22. · DOI
  19. Pintus, 2013, The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain, J. Biomol. Struct. Dyn., 31, 78, 10.1080/07391102.2012.691364 · DOI
  20. Balasundaram, A., and Doss, C.G.P. (2022). Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach. Int. J. Mol. Sci., 23. · DOI · Paper page
  21. Klemke, L., Fehlau, C.F., Winkler, N., Toboll, F., Singh, S.K., Moll, U.M., and Schulz-Heddergott, R. (2021). The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Front. Oncol., 11. · DOI
  22. Wang, 2019, It takes a team: A gain-of-function story of p53-R249S, J. Mol. Cell Biol., 11, 277, 10.1093/jmcb/mjy086 · DOI
  23. Zhang, J., Liu, M., Fang, Y., Li, J., Chen, Y., and Jiao, S. (2022). TP53 R273C Mutation Is Associated with Poor Prognosis in LGG Patients. Front. Genet., 13. · DOI
  24. Garg, 2019, Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties, Biophys. J., 118, 720, 10.1016/j.bpj.2019.12.015 · DOI
  25. Calhoun, 2011, Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain, Biochemistry, 50, 5345, 10.1021/bi200192j · DOI
  26. Zhang, 2017, TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer, Diagn. Pathol., 12, 16, 10.1186/s13000-017-0605-8 · DOI
  27. Kucab, 2010, Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model, FEBS J., 277, 2567
  28. Guha, 2017, Inherited TP53 Mutations and the Li-Fraumeni Syndrome, Cold Spring Harb. Perspect. Med., 7, a026187, 10.1101/cshperspect.a026187 · DOI · Paper page
  29. Zanier, 2016, HPV-mediated inactivation of tumor suppressor p53, Cell Cycle, 15, 2231, 10.1080/15384101.2016.1191257 · DOI
  30. Zong, 2024, Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis, Cell, 187, 2375, 10.1016/j.cell.2024.04.002 · DOI · Paper page
  31. Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat. Commun., 4, 2359, 10.1038/ncomms3359 · DOI
  32. Izquierdo, 2022, Extracellular vesicles and PDL1 suppress macrophages inducing therapy resistance in TP53-deficient B-cell malignancies, Blood, 139, 3617, 10.1182/blood.2021014007 · DOI
  33. Efe, 2023, p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression, Cancer Discov., 13, 2632, 10.1158/2159-8290.CD-23-0601 · DOI
  34. Siolas, 2021, Gain-of-function p53(R172H) mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy, Cell Rep., 36, 109578, 10.1016/j.celrep.2021.109578 · DOI
  35. Cooks, 2018, Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246, Nat. Commun., 9, 771, 10.1038/s41467-018-03224-w · DOI · Paper page
  36. Ghosh, 2021, Mutant p53 suppresses innate immune signaling to promote tumorigenesis, Cancer Cell, 39, 494, 10.1016/j.ccell.2021.01.003 · DOI · Paper page
  37. Martin, 2021, The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation, Science, 373, 1327, 10.1126/science.abg5784 · DOI
  38. Aptsiauri, 2022, The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes, Clin. Cancer Res., 28, 5021, 10.1158/1078-0432.CCR-21-3501 · DOI
  39. Zhu, 1999, p53 induces TAP1 and enhances the transport of MHC class I peptides, Oncogene, 18, 7740, 10.1038/sj.onc.1203235 · DOI
  40. Ho, 2022, Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation, Blood, 140, 1167, 10.1182/blood.2022016082 · DOI
  41. Schmaltz, 2002, T cells require TRAIL for optimal graft-versus-tumor activity, Nat. Med., 8, 1433, 10.1038/nm1202-797 · DOI · Paper page
  42. Costa, 2020, P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma, Cell Death Dis., 11, 748, 10.1038/s41419-020-02940-w · DOI
  43. Langenbach, 2023, MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production, Mol. Cancer Res., 21, 849, 10.1158/1541-7786.MCR-22-0898 · DOI
  44. Winter, 2023, The Battle within: AML´s p53 Strategies to Evade T-Cell Attack, Blood, 142, 1411, 10.1182/blood-2023-173826 · doi:10.1182/blood-2023-173826
  45. Liao, 1991, MHC Class I Deficiency: Susceptibility to Natural Killer (NK) Cells and Impaired NK Activity, Science, 253, 199, 10.1126/science.1853205 · DOI · Paper page
  46. Wolf, 2022, Roles of natural killer cells in immunity to cancer, and applications to immunotherapy, Nat. Rev. Immunol., 23, 90, 10.1038/s41577-022-00732-1 · DOI · Paper page
  47. Veneziani, 2021, Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors, Cancer Immunol. Res., 9, 170, 10.1158/2326-6066.CIR-20-0313 · DOI
  48. Pan, 2022, Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis, Cell, 185, 1521, 10.1016/j.cell.2022.03.030 · DOI · Paper page
  49. Weiskopf, 2015, Macrophages are critical effectors of antibody therapies for cancer, mAbs, 7, 303, 10.1080/19420862.2015.1011450 · DOI · Paper page
  50. Zhang, 2014, The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop, Cell Rep., 6, 421, 10.1016/j.celrep.2014.01.003 · DOI · Paper page
  51. Blagih, 2020, Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses, Cell Rep., 30, 481, 10.1016/j.celrep.2019.12.028 · DOI · Paper page
  52. Onkar, 2022, The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes, Cancer Discov., 13, 23, 10.1158/2159-8290.CD-22-0475 · DOI · Paper page
  53. Christofides, 2022, The complex role of tumor-infiltrating macrophages, Nat. Immunol., 23, 1148, 10.1038/s41590-022-01267-2 · DOI · Paper page
  54. Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat. Med., 19, 1423, 10.1038/nm.3394 · DOI · Paper page
  55. Li, 2014, A unique role for p53 in the regulation of M2 macrophage polarization, Cell Death Differ., 22, 1081, 10.1038/cdd.2014.212 · DOI · Paper page
  56. Paluskievicz, C.M., Cao, X., Abdi, R., Zheng, P., Liu, Y., and Bromberg, J.S. (2019). T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Front. Immunol., 10. · DOI · Paper page
  57. Yang, 2012, TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma, Cancer Cell, 22, 291, 10.1016/j.ccr.2012.07.023 · DOI · Paper page
  58. Abolhalaj, 2022, Transcriptional profiling demonstrates altered characteristics of CD8(+) cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia, Cancer Med., 11, 3023, 10.1002/cam4.4661 · DOI
  59. Shouval, 2022, Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy, J. Clin. Oncol., 40, 369, 10.1200/JCO.21.02143 · DOI
  60. Zhang, 2021, Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study, Cancer Med., 10, 3165, 10.1002/cam4.3763 · DOI
  61. Middeke, 2016, TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation, Br. J. Haematol., 172, 914, 10.1111/bjh.13912 · DOI
  62. Ando, 2023, Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study), Br. J. Cancer, 129, 1032, 10.1038/s41416-023-02378-9 · DOI
  63. Wang, 2021, PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab, Lung Cancer, 151, 76, 10.1016/j.lungcan.2020.11.006 · DOI
  64. Carlisle, 2018, Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC), J. Clin. Oncol., 36, e21090, 10.1200/JCO.2018.36.15_suppl.e21090 · doi:10.1200/jco.2018.36.15_suppl.e21090
  65. Zhu, 2023, Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden, Cancer Cell, 41, 1731, 10.1016/j.ccell.2023.09.006 · DOI · Paper page
  66. Kim, 2023, TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors, Cancer Med., 12, 12438, 10.1002/cam4.5953 · DOI · Paper page
  67. Vadakekolathu, 2020, TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML, Blood Adv., 4, 5011, 10.1182/bloodadvances.2020002512 · DOI
  68. Nag, 2013, The MDM2-p53 pathway revisited, J. Biomed. Res., 27, 254, 10.7555/JBR.27.20130030 · DOI · Paper page
  69. Hassin, 2022, Drugging p53 in cancer: One protein, many targets, Nat. Rev. Drug Discov., 22, 127, 10.1038/s41573-022-00571-8 · DOI · Paper page
  70. McKean, 2022, Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors, J. Clin. Oncol., 40, 9517, 10.1200/JCO.2022.40.16_suppl.9517 · DOI
  71. Focaccetti, C., Benvenuto, M., Pighi, C., Vitelli, A., Napolitano, F., Cotugno, N., Fruci, D., Palma, P., Rossi, P., and Bei, R. (2022). DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: A proof-of-concept study. Front. Immunol., 13. · DOI
  72. Roshandel, 2022, Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors, Health Sci. Rep., 5, e536, 10.1002/hsr2.536 · DOI
  73. Amouzegar, A., Chelvanambi, M., Filderman, J.N., Storkus, W.J., and Luke, J.J. (2021). STING Agonists as Cancer Therapeutics. Cancers, 13. · DOI · Paper page
  74. Diepstraten, 2024, Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers, Cancer Cell, 42, 850, 10.1016/j.ccell.2024.04.004 · DOI
  75. Park, 2022, Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors, ESMO Open, 7, 100573, 10.1016/j.esmoop.2022.100573 · DOI
  76. Xiao, 2024, Characterization of the generic mutant p53-rescue compounds in a broad range of assays, Cancer Cell, 42, 325, 10.1016/j.ccell.2024.01.008 · DOI
  77. Kim, 2018, Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor, OncoImmunology, 7, e1484982, 10.1080/2162402X.2018.1484982 · DOI
  78. Leung, 2021, A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer, J. Clin. Oncol., 39, 413, 10.1200/JCO.2021.39.15_suppl.4139 · DOI
  79. Lo, 2019, Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer, Cancer Immunol. Res., 7, 534, 10.1158/2326-6066.CIR-18-0686 · DOI · Paper page
  80. Kim, 2022, Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors, Cancer Immunol. Res., 10, 932, 10.1158/2326-6066.CIR-22-0040 · DOI · Paper page
  81. Cui, Y., and Guo, G. (2016). Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. Int. J. Mol. Sci., 17. · DOI
  82. Jaiswal, 2020, Clonal hematopoiesis and nonhematologic disorders, Blood, 136, 1606

Cited by

See all 68

Metadata

Authors
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S.
Affiliations
  • Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore
  • Duke-NUS Medical School, Singapore 169857, Singapore
Venue
Cancers
Publisher
MDPI AG
Published
2024-09-03
Volume
16
Issue
17
Pages
3069
ISSN
2072-6694
Cited by
68
References
19
Language
en
Funders
Paris-NUS Call (ANR-18-IDEX-0001)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. https://app.cochat.ai/papers/10.3390/cancers16173069
The paper
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024). TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. Cancers. https://doi.org/10.3390/cancers16173069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.